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ORIGINAL ARTICLE
Estrogens protect male mice from obesity complications and
inﬂuence glucocorticoid metabolism
RS Dakin, BR Walker, JR Seckl, PWF Hadoke and AJ Drake
BACKGROUND: Although the prevalence of obesity is higher among women than men, they are somewhat protected from the
associated cardiometabolic consequences. The increase in cardiovascular disease risk seen after the menopause suggests a role for
estrogens. There is also growing evidence for the importance of estrogen on body fat and metabolism in males. We hypothesized
that that estrogen administration would ameliorate the adverse effects of obesity on metabolic parameters in males.
METHODS: Male and female C57Bl/6 mice were fed control or obesogenic (DIO) diets from 5 weeks of age until adulthood. Glucose
tolerance testing was performed at 13 weeks of age. Mice were killed at 15 weeks of age and liver and adipose tissue were collected
for analysis of gene expression. A second cohort of male mice underwent the same experimental design with the addition of
estradiol pellet implantation or sham surgery at 6 weeks.
RESULTS: DIO males had greater mesenteric adipose deposition and more severe increases in plasma glucose, insulin and lipids
than females. Treatment of males with estradiol from 6 weeks of age prevented DIO-induced increases in adipose tissue mass and
alterations in glucose–insulin homeostasis. We also identiﬁed sex differences in the transcript levels and activity of hepatic and
adipose glucocorticoid metabolizing enzymes. Estrogen treatment feminized the pattern of DIO-induced changes in glucocorticoid
metabolism, rendering males similar to females.
CONCLUSIONS: Thus, DIO induces sex-speciﬁc changes in glucose–insulin homeostasis, which are ameliorated in males treated
with estrogen, highlighting the importance of sex steroids in metabolism. Given that altered peripheral glucocorticoid metabolism
has been observed in rodent and human obesity, our results also suggest that sexually dimorphic expression and activity of
glucocorticoid metabolizing enzymes may have a role in the differential metabolic responses to obesity in males and females.
International Journal of Obesity advance online publication, 30 June 2015; doi:10.1038/ijo.2015.102
INTRODUCTION
There has been a rapid increase in the worldwide prevalence of
obesity over recent decades, with a parallel increase in obesity-
associated cardiometabolic disorders.1 Although the prevalence of
obesity is higher among women, they may be somewhat
protected from the associated cardiometabolic consequences, at
least until the menopause.2 This is also the case in rodents: male
mice are more prone to diet-induced obesity3,4 and metabolic
dysfunction5,6 than females and there are sex differences in the
response to a high-fat diet in genetic models of obesity and
diabetes in rats.7,8 A role for sex steroids, particularly estrogens, in
modulating glucose and insulin homeostasis is supported by
observations in humans: pre-menopausal women have higher
insulin sensitivity when compared with age-matched men;9,10 and
following the menopause, women tend to accumulate visceral fat
and become more insulin resistant, with a consequent increase in
the risk of type 2 diabetes.11 An increasing body of evidence
suggests that estrogens also have important beneﬁcial effects on
body fat and metabolism in males.12–15 We used a mouse model
of diet-induced obesity to investigate sex differences in suscept-
ibility to the metabolic consequences of obesity by addressing the
hypothesis that estrogen treatment in males would ameliorate the
adverse effects of diet-induced obesity on metabolic parameters.
Given that altered peripheral glucocorticoid metabolism has been
observed in rodent and human obesity, we also sought to explore
the potential role of sex differences in glucocorticoid metabolism.
MATERIALS AND METHODS
Animals and experimental design
All animal procedures were carried out under UK Home Ofﬁce license
approval under the Animals (Scientiﬁc Procedures) Act, 1986, and with
local ethical committee approval. C57Bl/6 mice were bred in-house and
maintained under controlled conditions of light (on 0700–1900 hours) and
temperature (21 °C) with free access to food and water. Males and females
(n=8 per group) were weaned aged 3 weeks onto standard chow (Special
Diet Services Witham, Essex, UK) and at 5 weeks were randomly assigned
by a technician not involved in the research to high-fat, high-sugar
‘obesogenic’ diet (DIO: D12328, Research Diets, New Brunswick, NJ, USA) or
control diet (CON: D12331, Research Diets). D12328 induces obesity in
rodents16 and the corresponding control diet was matched in terms of
protein and micronutrient content. Animals were weighed weekly and
after 8 weeks were individually housed to allow for metabolic investiga-
tion. Animals were killed aged 15 weeks by CO2 asphyxiation, between
1400 and 1600 hours following a 6-h fast, and trunk blood was collected.
Tissues were dissected immediately, weighed and snap frozen on dry ice.
Females were killed during estrus, conﬁrmed by vaginal smear examina-
tion showing exclusively non-nucleated corniﬁed epithelial cells.
In a separate experiment, pre-pubertal C57Bl/6 mice of both sexes were
killed following weaning (3–4 weeks of age; n= 7 per group), after a
physical examination to exclude puberty (vaginal opening in females and
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balanopreputial separation in males). Tissues were dissected immediately,
weighed and snap frozen on dry ice.
A second cohort of male mice underwent the same experimental design
with the addition of estradiol pellet implantation or sham surgery at
6 weeks (1 week post initiation of experimental diet; n= 11 per sham
group, 12 per estradiol group). Animals were anaesthetized using
isoﬂurane and 90-day, 0.25mg 17β-estradiol pellets (Innovative Research
of America, Sarasota, FL, USA) implanted subcutaneously in the left mid-
dorsal region. Skin incisions were closed using silk sutures. Sham-operated
animals underwent the same surgical procedure with the exclusion of the
pellet being inserted. Animals were killed aged 15 weeks using the
same protocol as listed in experimental design. Plasma concentrations of
17β-estradiol were determined using an enzyme-linked immunosorbent
assay (Calbiotech, Spring Valley, CA, USA) on blood samples taken when
animals were killed.
Metabolic measures
Glucose tolerance tests were performed at 13 weeks of age; animals were
fasted for 6 h and tests commenced at 1400 hours. A basal blood sample
was taken by tail nick followed by an intraperitoneal injection of a glucose
load (2 g kg− 1) and blood samples collected 15, 30, 60 and 90min post
injection. Samples were centrifuged at 2.3 g for 10 min and plasma stored
at − 20 °C. Plasma glucose, cholesterol and triglyceride concentrations
were measured by enzymatic methods (ThermoElectron, Pittsburgh, PA,
USA). Insulin (Crystal Chem Inc., Chicago, IL, USA) and testosterone
(Demeditec Diagnostics GmbH, Kiel, Germany) were determined by
enzyme-linked immunosorbent assay. Non-esteriﬁed fatty acid concentra-
tions were determined using a kit (Wako Diagnostics, Richmond, VA, USA).
At 14 weeks of age, plasma corticosterone was measured in tail tip blood
samples taken at 0700 and 1900 within 1min of cage disturbance, using an
in-house radio-immuno assay.17 Hepatic triglyceride was extracted by
saponiﬁcation18 and quantiﬁed as in plasma.
Quantiﬁcation of mRNA
Total RNA was extracted from snap frozen tissues using an RNeasy mini kit
(Qiagen, West Sussex, UK) and reverse transcribed (250 ng liver and 500 ng
adipose) using the Access RT-PCR kit from Promega (Hampshire, UK). Real-
time PCR was performed using a Roche Lightcycler 480 (Roche Diagnostics
Ltd., Sussex, UK) with Universal Probes master mix (Roche) and thermal
cycler parameters recommended by the manufacturer. PCR was performed
in triplicate in a total volume of 10 μl containing 2 μl of complementary
DNA, 5 μl Roche master mix, 12 pmol μl− 1 primers and 4 pmol μl− 1 probe
(Universal probe library, Roche); primer sequences and probe numbers are
given in Table 1. A standard curve was constructed for each primer/probe
set using a serial dilution of complementary DNA pooled from all samples.
Expression was corrected for cyclophilin A (Taqman gene expression assay
Applied Biosytems, Warrington, UK; Mm02342430_g1) in the liver and
beta-actin (Mm01215647_g1) in adipose tissue.
11β-HSD1 activity assay
11β-HSD1 is a reductase in vivo, converting inactive 11-dehydrocorticosterone
to corticosterone. However, in vitro, dehydrogenase activity predominates and
measurements of reductase activity are confounded by competition with other
enzymes. Therefore, as an index of total 11β-HSD1 protein, we measured
enzyme activity as conversion of corticosterone to 11-dehydrocorticosterone in
the presence of an excess of the cofactor NADP+ as previously described.19
Reactions were optimized to ensure ﬁrst-order kinetics (liver 0.025mgml−1 for
2–4 h; adipose 0.025–0.1mgml−1 for 16–24 h).
Statistical analysis
Data presented are mean± s.e.m. Numbers were based on our previous
studies.20 Statistical analysis was carried out by t-testing, two-way or
repeated measures analysis of variance as appropriate. Data were normally
distributed and groups compared had similar variances. Values were
considered different when Po0.05.
RESULTS
Effects of DIO on glucose homeostasis, lipids and plasma
corticosterone in males and females
Consumption of an obesogenic diet caused a signiﬁcant increase
in body weight in males (Figure 1a) and an increase in adipose
tissue weights in both the sexes (Figure 1b). Plasma triglyceride
concentrations were lower in CON females compared with males
(Table 2) but plasma cholesterol and plasma and hepatic
triglyceride concentrations were similarly increased by DIO in
both the sexes (Table 2). DIO increased plasma concentrations of
glucose (Figure 1c) and insulin (Figure 1d) following a glucose
load, with a substantially larger effect in males. In mice on control
diet, nadir plasma corticosterone concentrations were comparable
in both the sexes; however, peak concentrations were higher in
females than in males (Table 2). Peak plasma corticosterone was
reduced by DIO in both the sexes (Table 2).
Effects of estradiol administration in male mice
At the end of the experiment, plasma estradiol concentrations
were increased in males treated with estradiol compared with the
sham group, and were signiﬁcantly higher in the estradiol-treated
DIO group compared with all other groups (Table 3). Plasma
testosterone concentrations were reduced by estradiol treatment
but unaffected by diet (Table 3). Estradiol administration reduced
weight gain (Figure 2a) and adipose tissue weight (Figure 2b) in
both CON and DIO males. Estradiol also ameliorated the increase
in plasma glucose and insulin caused by DIO (Figures 2c and d)
but did not affect plasma triglyceride or cholesterol concentra-
tions (Table 3). However, estrogen treatment reversed the
DIO-associated increase in hepatic triglyceride (Table 3). Nadir
plasma concentrations of corticosterone were higher in estradiol-
treated males but were unaffected by DIO; peak concentrations
were comparable in all the groups (Table 3).
Glucocorticoid metabolism in DIO and the effects of estrogen
Given the sex differences in circulating corticosterone levels and
the fact that altered glucocorticoid metabolism may contribute to
the pathogenesis of obesity and related metabolic disorders,21 we
proceeded to measure transcript and expression levels of
glucocorticoid metabolizing enzymes including 11β-hydroxy-
steroid dehydrogenase type 1 (11β-HSD1, which reactivates
glucocorticoids from their inert 11-keto metabolites) and the
levels of the A-ring reductases (5α- and 5β-reductase, which
convert glucocorticoids into their dihydro metabolites). Females
had lower hepatic transcript levels of 5α-reductase and higher
transcript levels of 5β-reductase than males (Figure 3a). There was
a trend for females to have higher hepatic transcript levels of 11β-
HSD1 than males (P= 0.057; Figure 3a) but there were no
differences in hepatic enzyme activity (Figure 3b). In subcutaneous
fat, although there were no sex differences in transcript levels of
11β-HSD1 (Figure 3c), enzyme activity was lower in females
compared with males (Figure 3d). DIO increased hepatic transcript
levels of 11β-HSD1 in males but not in females (Figure 3a),
Table 1. Primer sequences for quantitative real-time PCR
Gene accession number Primer sequence (5′-3′)
Probe
number
5α reductase (5αR)
(NM_175283.3)
For—gggaaactggatacaaaataccc
Rev—ccacgagctccccaaaata
41
5β-reductase (5βR)
(NM_145364.2)
For—gaaaagatagcagaagggaaggt
Rev—gggacatgctctgtattccataa
103
11β hydroxysteroid
dehydrogenase type 1
(11β-HSD1) (NM_008288.2)
For—tctacaaatgaagagttcagaccag
Rev—gccccagtgacaatcactt
1
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although there were no changes in hepatic enzyme activity
(Figure 3b). There was no effect of DIO on hepatic transcript levels
of 5α-reductase or 5β-reductase in either sex (Figure 3a). In
subcutaneous adipose tissue, DIO reduced 11β-HSD1 expression
(Figure 3c) and activity (Figure 3d) in both the sexes.
To investigate when the sex differences in glucocorticoid
metabolizing enzymes became apparent, a cohort of mice were
killed before puberty (when sex-steroid concentrations are low)
and enzyme expression and activity were determined. In
pre-pubertal mice, there was a trend for a lower expression of
hepatic 5α-reductase in females (Figure 4a), but no differences in
the expression of hepatic 5β-reductase or in the expression or
activity of 11β-HSD1 (Figures 4a and b). Furthermore, expression
and activity of 11β-HSD1 in adipose tissue were comparable in
male and female pre-pubertal mice (Figures 4c and d).
In adult males, estradiol increased hepatic transcript levels, but
not enzyme activity, of 11β-HSD1 (Figures 5a and b). Analysis by
two-way analysis of variance revealed an effect of estradiol to
reduce hepatic transcript levels of 5α-reductase and increase
transcript levels of 5β-reductase in both CON and DIO males
(Figure 5a). In adipose tissue, by contrast with the liver, analysis by
two-way analysis of variance revealed an overall effect of estradiol
to reduce both the expression (Figure 5c) and activity (Figure 5d)
of 11β-HSD1 in CON and DIO males. As DIO reduces both
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Figure 1. Effect of obesogenic diet and sex on adiposity and metabolism in C57Bl/6 mice. Male and female mice were fed control (CON) or
obesogenic diet (DIO) from 5 weeks of age. (a) Body weight during the study, (b) adipose mass as percentage of body weight at killing. SC,
subcutaneous; Mes, mesenteric; RP, retroperitoneal; Epi, epididymal. Plasma glucose (c) and insulin (d) during a glucose tolerance test. Area
under curve (AUC) glucose: male CON 1003.2± 97.5; male DIO 1285.2± 93.7; female CON 859.1± 65.8; female DIO 961.5± 126.3. AUC insulin:
male CON 38.9± 6.9; male DIO 160.0± 22.3; female CON 28.9± 1.9; female DIO 55.7± 7.4. Data are mean± s.e.m., n= 8 per group, analyzed by
repeated measures analysis of variance (ANOVA) (a, c and d) and two-way ANOVA (b), repeated measures where necessary. Effect of diet
**Po0.01, ***Po0.001; effect of sex †Po0.05, ††Po0.01, †††Po0.001.
Table 2. Concentrations of lipids and corticosterone in obese and control mice
Males Females Effect of diet
P-value
Effect of sex
P-value
Interaction diet and sex
P-value
CON DIO CON DIO
Fasting plasma triglyceride (mmol l− 1) 0.57± 0.03 0.78± 0.05 0.41± 0.03 0.54± 0.02 0.000027 0.000005 0.21
Total plasma cholesterol (mmol l− 1) 1.71± 0.13 2.67± 0.23 1.53± 0.17 2.86± 0.16 o0.000001 0.55 0.56
Hepatic triglyceride (nmol mg− 1) 27.5± 3.7 60.6± 8.6 26.5± 3.0 58.5± 3.8 0.000001 0.77 0.93
Nadir plasma corticosterone (nM) 64.8± 8.0 70.8± 7.6 66.6± 14.3 62.1± 10.0 0.94 0.74 0.60
Peak plasma corticosterone (nM) 282.0± 43.0 177.0± 26.2 457.3± 62.0 375.0± 33.1 0.03 0.0001 0.79
Male and female mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age. Plasma lipid and corticosterone levels were measured in samples
taken during metabolic tests. Hepatic triglyceride was analyzed in post-mortem tissue. Data are mean± s.e.m., analyzed by two-way analysis of variance n= 8
per group.
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expression and activity of 11β-HSD1 in adipose, resulting in lower
baseline 11β-HSD1 levels, there was a much smaller relative
reduction in both expression and activity in the estradiol-treated
DIO group (Figures 5c and d).
DISCUSSION
Our data conﬁrm previous reports showing that male mice are
markedly more susceptible than females to the effects of an
obesogenic diet.3–6 In postmenopausal women and in female
animal models, lower estrogen levels are associated with
increased visceral adiposity22,23 and estrogen replacement
improves glucose–insulin homeostasis.24,25 We show that estro-
gen treatment of males is associated with an improvement in
weight gain and DIO-induced metabolic changes, supporting the
concept that estrogen has an important role in the control of
metabolism and adiposity. There is growing evidence for a
fundamental role for estrogen in the regulation of obesity and
related metabolic disorders in males12–14 and recent data from
rodent studies suggest that hepatic estrogen signaling has a key
role in the prevention of high-fat diet-induced insulin resistance in
males.26 Indeed, the aromatization of testosterone to estradiol
may underpin many of the physiological effects which have
generally been attributed to the action of testosterone, for
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Figure 2. Effect of obesogenic diet and estrogen treatment on adiposity and metabolism in male mice. Male mice were fed control (CON) or
obesogenic (DIO) diet from 5 weeks of age and at 6 weeks underwent implantation of a continuous release 17β-estradiol pellet (estradiol) or
sham surgery (sham). (a) Body weight over duration of study. (b) Adipose mass as percentage of body weight. SC, subcutaneous;
Mes, mesenteric; RP, retroperitoneal; Epi, epididymal. Plasma glucose (c) and insulin (d) during a glucose tolerance test. AUC glucose: sham
CON 859.2± 123.7; sham DIO 1290.6± 110.8; estrodiol CON 596.9± 32.3; estrodiol DIO 759.3± 46.3. AUC insulin: sham CON 41.0± 5.8; sham
DIO 185.8± 9.9; estrodiol CON 44.8± 10.7; estrodiol DIO 55.0± 6.5. Data are mean± s.e.m., n= 11 per sham group, 12 per estradiol group,
analyzed by repeated measures analysis of variance (ANOVA) (a, c and d) or two-way ANOVA (b), repeated measures where necessary. Effect of
diet ***Po0.001; effect of estradiol †††Po0.001; interaction between effects ∫Po0.05, ∫∫Po0.01, ∫∫∫Po0.001.
Table 3. Concentrations of lipids, corticosterone and testosterone in male obese and control mice treated with estradiol
Sham Estradiol Effect of diet
P-value
Effect of estradiol
P-value
Interaction of effects
P-value
CON DIO CON DIO
Fasting plasma triglyceride (mmol l− 1) 0.55± 0.05 0.94± 0.09 0.59± 0.06 0.81± 0.06 0.000024 0.49 0.20
Total plasma cholesterol (mmol l− 1) 2.19± 0.31 3.59± 0.44 2.05± 0.22 3.16± 0.21 0.00016 0.34 0.62
Hepatic triglyceride (nmol mg− 1) 19.0± 2.7 48.8± 6.9 25.9± 2.8 27.9± 3.3 0.0005 0.10 0.0019
Nadir plasma corticosterone (nM) 15.3± 3.5 17.0± 2.9 50.0± 11.7 39.6± 6.0 0.55 0.00031 0.41
Peak plasma corticosterone (nM) 148.7± 18.1 178.9± 24.5 240.2± 35.5 173.1± 30.6 0.52 0.14 0.09
Plasma estradiol (pgml− 1) 2.5± 0.4 2.0± 0.3 6.9± 1.2 21.6± 4.7 0.09 o0.000001 0.011
Plasma testosterone (ngml− 1) 2.5± 1.3 2.2± 1.4 0.4± 0.1 0.5± 0.2 0.703 0.021 0.95
Male mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous release
17β-estradiol pellet (estradiol) or sham surgery (sham). Plasma lipid and corticosterone levels were measured in samples taken during metabolic tests. Hepatic
triglyceride was analyzed in post-mortem tissue. Data are mean± s.e.m., analyzed by two-way analysis of variance, plasma estradiol concentrations were log
transformed before analysis. n= 11 per sham group, 12 per estradiol group.
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example, the prevention of visceral adiposity.12 Estrogen may also
have a role in the control of hepatic lipid metabolism and hepatic
lipid deposition,26–28 and estrogen treatment in DIO males
abolished the DIO-induced increase in the accumulation of
hepatic triglyceride. Intriguingly, this occurred in the absence of
any effect of estradiol on plasma triglyceride and cholesterol
concentrations. Estrogen may inﬂuence appetite and energy
expenditure.29 Although we did not measure food intake and
energy expenditure in this study, data from female rodents
suggest that ovariectomy induces an increase in food intake and
estrogen replacement decreases food intake.29 However, hyper-
phagia does not fully account for the changes in metabolism and
development of obesity after ovariectomy.29 Our ﬁndings,
showing the importance of estrogen signaling in regulating body
weight, glucose–insulin homeostasis and hepatic triglyceride
content are in agreement with studies in mice lacking the
estrogen receptor (ER). Mice lacking ER have increased adipose
tissue, higher fasting blood glucose and insulin30 and hepatic
insulin resistance with altered hepatic lipid handling.26,31 Further-
more, deletion of ERα in mice blocks the antiobesity effects of
estrogen replacement.29 Male mice lacking ER speciﬁcally in the
liver show reduced insulin sensitivity.26 Conversely, hepatic ERα
overexpression is associated with markedly reduced hepatic
triglyceride content and improved insulin sensitivity.32
There were sex differences in circulating corticosterone concen-
trations and, as in previous rodent studies, DIO reduced
peak corticosterone concentrations in both the sexes,33,34 which
may reﬂect altered peripheral glucocorticoid clearance.35,36
As altered glucocorticoid metabolism may contribute to the
pathogenesis of obesity and related metabolic disorders,21 we
hypothesized that some of the protective effects of estrogen might
be due to effects on adipose and/or hepatic glucocorticoid
metabolism. There are sex differences in the expression and activity
of glucocorticoid metabolizing enzymes in humans, with lower
expression and activity of hepatic and adipose 11β-HSD1 in
females37 and estrogen regulates 11β-HSD1 expression and activity
in the rat liver38 and kidney,39 and in rodent and human
adipocytes.40,41 We observed sex-speciﬁc responses of glucocorticoid
metabolizing enzymes to diet-induced obesity, and estrogen therapy
feminized the pattern of enzyme expression and activity in males. We
observed no sex differences in the expression or activity of hepatic or
adipose 11β-HSD1 in pre-pubertal mice, although there were clear
sex differences in adult animals. 11β-HSD1 messenger RNA (mRNA)
and activity were higher in lean males compared with females, a
ﬁnding which has also been reported in humans.37 This predicts
greater regeneration of corticosterone in adult male adipose tissue
and may be a disadvantage given that mice overexpressing 11β-
HSD1 in adipose tissue exhibit intra-abdominal obesity and
metabolic dysfunction.42 The DIO-induced reduction in 11β-HSD1
mRNA and activity in subcutaneous adipose tissue that occurred in
both the sexes in our study has previously been reported in male
rodents34,43 and has been proposed as a protective mechanism to
reduce both circulating glucocorticoid concentrations and local
glucocorticoid signaling.34,43 Indeed, 11β-HSD1-knockout mice, or
mice treated with selective 11β-HSD1 inhibitors, are resistant to
obesity and hyperglycemia when fed a high-fat diet,44–48 although,
notably, these studies were carried out in male animals. Lower
adipose 11β-HSD1 in females compared with males may, therefore,
contribute to the relative protection of females from the metabolic
effects of obesity. Consistent with this hypothesis, the estrogen-
induced reduction in adipose 11β-HSD1 mRNA and activity may be
one mechanism for the protection from the metabolic consequences
of high-fat diet in estrogen-treated males. However, the relative
importance of changes in adipose tissue 11β-HSD1 in mediating the
metabolic response to DIO remains unclear, as DIO itself is associated
with a profound reduction in the expression and activity of adipose
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Figure 3. Effect of obesogenic diet and sex on glucocorticoid metabolism. Male and female mice were fed control (CON) or obesogenic diet
(DIO) from 5 weeks of age. mRNA abundance of glucocorticoid metabolizing genes was assessed using real-time PCR in the liver (a) and
subcutaneous adipose (c). Activity of 11β-HSD1 was analyzed in samples from the same tissues (b and d). Data are mean± s.e.m., n= 8 per
group, analyzed by two-way analysis of variance. Effect of diet ***Po0.001; effect of sex †††Po0.001; interaction between diet and sex
∫∫Po0.01.
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11β-HSD1 in both the sexes, yet the metabolic phenotype is more
severe in DIO males.
Sex differences in the expression of 5α- and 5β-reductase also
became apparent after puberty. As 5α-reduced glucocorticoid
metabolites are active at the glucocorticoid receptor,49 the
increased expression of 5α-reductase and lower expression of
5β-reductase in males predict increased hepatic concentrations
of active glucocorticoids in males and may render them more
susceptible to the effects of a high-fat diet. Indeed, in humans
obesity is associated with alterations in the ratio of urinary 5α- and
5β-reduced glucocorticoid metabolites, with an increased propor-
tion of cortisol metabolized by 5α-reduction.21,36,50 Estradiol
treatment in males decreased hepatic 5α-reductase and increased
5β-reductase expression, resulting in a similar expression pattern
to that in females. As 5β-reductase can metabolize both
corticosterone and 11-dehydrocorticosterone, and its metabolites
are not active at glucocorticoid receptor, this predicts reduced
intrahepatic glucocorticoid signaling and may be one mechanism
by which estrogen treatment resulted in protection from the
metabolic consequences of exposure to a high-fat diet. Although
females, DIO males and estradiol-treated males had increased
hepatic 11β-HSD1 expression in comparison to lean males, this
was not reﬂected in differences in enzyme activity. We have
previously suggested that this discrepancy may reﬂect post-
transcriptional modiﬁcation.34 Intriguingly, the DIO-induced
increase in hepatic 11β-HSD1 and the reduction in peak
corticosterone were not present in the sham surgery DIO males
suggesting that there may be long-term effects of surgery on
glucocorticoid metabolism.
In terms of mechanisms, changes in 11β-HSD1 expression
following ovariectomy and estrogen treatment in female rats
could be due to reduced adiposity rather than increases in estradiol.51
However, both direct and indirect effects of estradiol on adipose
11β-HSD1 have been proposed: estradiol is a competitive inhibitor
of 11β-HSD1 in primary cultures of rat adipocytes40 and higher
adipose expression of 11β-HSD1 is found in postmenopausal
women.41 In our study, the lack of sex difference in adipose and
liver 11β-HSD1 expression and activity in pre-pubertal mice, when
sex-steroid concentrations are low, combined with the changes
with estrogen treatment in adult males are consistent with direct
regulation of glucocorticoid metabolism in adipose tissue.
Although estrogen may have an important inﬂuence on peripheral
glucocorticoid metabolism, there is increasing evidence for the
key role of insulin.52–55 In rodents, insulin senitization ameliorates
the obesity-induced changes in hepatic A-ring reductase expres-
sion and activity,55 and in humans, intravenous insulin acutely
increases cortisol regeneration by 11β-HSD1(ref. 54) and cortisol
production by 11β-HSD1 parallels the change in circulating insulin
concentrations following meals.52 Thus, the changes in hepatic
and adipose glucocorticoid metabolism seen in females and in
estrogen-treated males may additionally represent a downstream
effect of the marked improvement in insulin sensitivity. Finally, the
changes induced by estrogen treatment may also be attributed to
reduced testosterone levels in both CON and DIO males. However,
a recent study in humans in which endogenous testosterone and
estradiol were suppressed pharmacologically suggests that,
whereas androgen deﬁciency may account for decreases in lean
mass, estrogen deﬁciency is responsible for increases in body
fat.12 Nevertheless, altered estrogen/androgen balance may still
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Figure 4. Sex differences in hepatic and subcutaneous fat glucocorticoid metabolism in pre-pubertal mice. Male and female mice were killed
aged 3–4 weeks, before signs of puberty, and liver and subcutaneous adipose were collected. mRNA abundance of glucocorticoid
metabolizing genes was assessed using real-time PCR in liver (a) and subcutaneous fat (c) and 11β-HSD1 activity determined in liver (b) and
subcutaneous fat (d). Data are mean± s.e.m., n= 7 per group, analyzed by Student’s t-test.
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be of importance in the maintenance of normal physiology and
future studies in which testosterone levels are maintained at
physiological levels would help to determine the relative
importance of estrogens versus androgens.
Our hypothesis for this study was that estrogen treatment in
males would ameliorate the adverse effects of diet-induced
obesity on metabolic parameters. Consequently, we did not
assess the effects of administration of estradiol in females.
Estrogens may also have a role in mediating glucose–insulin
homeostasis in women and estrogen deﬁciency is associated with
an increasing risk of obesity, the metabolic syndrome and type 2
diabetes.29 In postmenopausal women, the administration of
estrogen can improve glucose homeostasis, insulin sensitivity and
lipid proﬁle.56–58 Studies using estrogen replacement in ovar-
iectomized mice have shown that estrogen protects against fatty
liver and may improve pathway-selective insulin resistance.28
In conclusion, our data support the importance of estrogen in
the apparent protection of females from the deleterious effects of
exposure to an obesogenic diet and provide further evidence for
the suggestion that manipulating estrogen signaling pathways
may represent an alternative/additional approach to the manage-
ment of the complications of obesity in males. In addition, they
suggest that sexually dimorphic expression and activity of
glucocorticoid metabolizing enzymes may contribute to gender
differences in metabolic responses to diet-induced obesity.
Understanding the molecular basis of sex differences in disease
risk may provide new approaches to the management of obesity-
associated metabolic disease.
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